Evidence map›Paper›PMID 31723371›Full record

ArticleScience and technology of advanced materials2019

Metal-organic framework-coated magnetite nanoparticles for synergistic magnetic hyperthermia and chemotherapy with pH-triggered drug release.

Jiajie Chen, Jiaxing Liu, Yaping Hu, Zhengfang Tian, Yufang Zhu

Abstract read
In one paragraph

Article in Science and technology of advanced materials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Nanosized metal-organic frameworks as unique platforms for bioapplications.Chemical communications (Cambridge, England) · 2023
    Review
  9. BioMOF-Based Anti-Cancer Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2023
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Recent Advances in Nanoscale Metal-Organic Frameworks Towards Cancer Cell Cytotoxicity: An Overview.Journal of inorganic and organometallic polymers and materials · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiajie ChenSchool of Materials Science and Engineering, University of Shanghai for Science and Technology, Shanghai, P. R. China.
Jiaxing LiuSchool of Materials Science and Engineering, University of Shanghai for Science and Technology, Shanghai, P. R. China.
Yaping HuSchool of Materials Science and Engineering, University of Shanghai for Science and Technology, Shanghai, P. R. China.
Zhengfang TianHubei Key Laboratory of Processing and Application of Catalytic Materials, College of Chemical Engineering, Huanggang Normal University, Huanggang, Hubei, P. R. China.
Yufang ZhuSchool of Materials Science and Engineering, University of Shanghai for Science and Technology, Shanghai, P. R. China.ORCID 0000-0001-9031-8861

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In nanoplatform-based tumor treatment, combining chemotherapy with hyperthermia therapy is an interesting strategy to achieve enhanced therapeutic efficacy with low dose of delivery drugs. Compared to photothermal therapy, magnetic hyperthermia has few restrictions on penetrating tissue by an alternating magnetic field, and thereby could cure various solid tumors, even deep-tissue ones. In this work, we proposed to construct magnetic nanocomposites (Fe

Indexed as

chemotherapymagnetic hyperthermiametal-organic frameworksMultifunctional nanoparticlessynergistic effect

Identifiers

PMID31723371
PMCPMC6844413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.